BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang R, Neighbors J, Schell T, Hohl R. Schweinfurthin induces ICD without ER stress and caspase activation. OncoImmunology 2022;11:2104551. [DOI: 10.1080/2162402x.2022.2104551] [Reference Citation Analysis]
2 Liu K, Sun Q, Liu Q, Li H, Zhang W, Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Biomedicine & Pharmacotherapy 2022;154:113618. [DOI: 10.1016/j.biopha.2022.113618] [Reference Citation Analysis]
3 Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Mol Cancer 2022;21:189. [PMID: 36175961 DOI: 10.1186/s12943-022-01656-z] [Reference Citation Analysis]
4 Xu Q, Yang H, Li M, He Z, Hong H, Peng Z. Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review. Medicine 2022;101:e30731. [DOI: 10.1097/md.0000000000030731] [Reference Citation Analysis]
5 Cao Y, Liu S, Ma Y, Ma L, Zu M, Sun J, Dai F, Duan L, Xiao B. Oral Nanomotor-Enabled Mucus Traverse and Tumor Penetration for Targeted Chemo-Sono-Immunotherapy against Colon Cancer. Small 2022;:e2203466. [PMID: 36117129 DOI: 10.1002/smll.202203466] [Reference Citation Analysis]
6 Miglietta G, Marinello J, Russo M, Capranico G. Ligands stimulating antitumour immunity as the next G-quadruplex challenge. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01649-y] [Reference Citation Analysis]
7 Shimu AS, Wei H, Li Q, Zheng X, Li B. The new progress in cancer immunotherapy. Clin Exp Med. [DOI: 10.1007/s10238-022-00887-0] [Reference Citation Analysis]
8 Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 2022;13:964442. [DOI: 10.3389/fimmu.2022.964442] [Reference Citation Analysis]
9 Lin Z, Wu Y, Xiao X, Zhang X, Wan J, Zheng T, Chen H, Liu T, Tang X. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy. Front Genet 2022;13:938510. [DOI: 10.3389/fgene.2022.938510] [Reference Citation Analysis]
10 Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
11 Cheng C, Zhuge L, Xiao X, Luan S, Yuan Y. Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. Front Oncol 2022;12:955163. [DOI: 10.3389/fonc.2022.955163] [Reference Citation Analysis]
12 Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 2022;12:958720. [DOI: 10.3389/fonc.2022.958720] [Reference Citation Analysis]
13 Liu J, Tao H, Yuan T, Li J, Li J, Liang H, Huang Z, Zhang E. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Front Immunol 2022;13:992611. [DOI: 10.3389/fimmu.2022.992611] [Reference Citation Analysis]
14 Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 2022. [PMID: 36045296 DOI: 10.1038/s41586-022-05140-y] [Reference Citation Analysis]
15 Shi Y, Zheng H, Guo Z, Deng R, Yu W, Song Y, Ding S. Effect of Helicobacter pylori on immunotherapy is gaining more attention. Helicobacter 2022;:e12925. [PMID: 36036113 DOI: 10.1111/hel.12925] [Reference Citation Analysis]
16 Chun J, Kang HN, Yi J, Hong SH, Park S, Jeong M. Bojungikki-Tang Enhances the Effect of PD-1 Blockade in a Syngeneic Murine Model of Lung Carcinoma. Processes 2022;10:1683. [DOI: 10.3390/pr10091683] [Reference Citation Analysis]
17 Zhao R, Li Z, Huang Y, Xiong C, Zhang C, Liang H, Xu J, Luo X, Endo M. A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma. Analytical Cellular Pathology 2022;2022:1-22. [DOI: 10.1155/2022/6711629] [Reference Citation Analysis]
18 Wu J, Guo Z, Ni W, Feng Y, Guo X, Meng M, Yuan Y, Lin L, Chen J, Tian H, Chen X. Novel Cocktail Therapy Based on a Nanocarrier with an Efficient Transcytosis Property Reverses the Dynamically Deteriorating Tumor Microenvironment for Enhanced Immunotherapy. Nano Lett 2022. [PMID: 35994713 DOI: 10.1021/acs.nanolett.2c02724] [Reference Citation Analysis]
19 Yang W, Han B, Chen Y, Geng F. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. Aging (Albany NY) 2022;14. [PMID: 35963646 DOI: 10.18632/aging.204224] [Reference Citation Analysis]
20 Chen P, Li Y, Wei P, Liang L, Li B, Cao Y, Han X, Wang Y, Duan X, Jia H, Zhao T, Ren J. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma. Int Immunopharmacol 2022;111:109127. [PMID: 35964407 DOI: 10.1016/j.intimp.2022.109127] [Reference Citation Analysis]
21 Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D, Wu K. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol 2022;15:104. [PMID: 35948909 DOI: 10.1186/s13045-022-01322-3] [Reference Citation Analysis]
22 Zhang W, Huang X. Stem cell membrane-camouflaged targeted delivery system in tumor. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Song H, Sun H, He N, Xu C, Wang Y, Du L, Liu Y, Wang Q, Ji K, Wang J, Zhang M, Gu Y, Zhang Y, Feng L, Tillement O, Wang W, Liu Q. Gadolinium-based ultra-small nanoparticles augment radiotherapy-induced T-cell response to synergize with checkpoint blockade immunotherapy. Nanoscale 2022. [PMID: 35904053 DOI: 10.1039/d2nr02620a] [Reference Citation Analysis]
24 Khatoon E, Parama D, Kumar A, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci 2022;:120827. [PMID: 35907493 DOI: 10.1016/j.lfs.2022.120827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Huo J, Wang Y, Fu W, Lu N, Liu Z. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol 2022;13:956090. [DOI: 10.3389/fimmu.2022.956090] [Reference Citation Analysis]
26 Costa B, Vale N. Dostarlimab: A Review. Biomolecules 2022;12:1031. [PMID: 35892341 DOI: 10.3390/biom12081031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zheng D, Hou X, Yu J, He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol 2022;13:928369. [DOI: 10.3389/fphar.2022.928369] [Reference Citation Analysis]
28 Luo K, Li N, Ye W, Gao H, Luo X, Cheng B. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy. Molecules 2022;27:4638. [DOI: 10.3390/molecules27144638] [Reference Citation Analysis]
29 Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, Wang Y, Li W. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 2022;15:94. [PMID: 35840984 DOI: 10.1186/s13045-022-01311-6] [Reference Citation Analysis]
30 Magnez R, Bailly C, Thuru X. Microscale Thermophoresis as a Tool to Study Protein Interactions and Their Implication in Human Diseases. IJMS 2022;23:7672. [DOI: 10.3390/ijms23147672] [Reference Citation Analysis]
31 Thuru X, Magnez R, El-bouazzati H, Vergoten G, Quesnel B, Bailly C. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers 2022;14:3368. [DOI: 10.3390/cancers14143368] [Reference Citation Analysis]
32 Zheng S, Liu B, Guan X. The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma. Front Oncol 2022;12:911285. [DOI: 10.3389/fonc.2022.911285] [Reference Citation Analysis]
33 Yamada Y, Sato Y, Nakamura T, Harashima H. Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control. J Control Release 2022;348:357-69. [PMID: 35623492 DOI: 10.1016/j.jconrel.2022.05.033] [Reference Citation Analysis]
34 Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol 2022;15:58. [PMID: 35551634 DOI: 10.1186/s13045-022-01278-4] [Reference Citation Analysis]
35 Ding Y, Wang L, Li H, Miao F, Zhang Z, Hu C, Yu W, Tang Q, Shao G. Application of lipid nanovesicle drug delivery system in cancer immunotherapy. J Nanobiotechnology 2022;20:214. [PMID: 35524277 DOI: 10.1186/s12951-022-01429-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Shurin MR, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. Journal of Clinical Investigation 2022;132:e159473. [DOI: 10.1172/jci159473] [Reference Citation Analysis]
37 Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol 2022;11:11. [PMID: 35236415 DOI: 10.1186/s40164-022-00263-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]